Hillary Clinton slammed Mylan's decision to raise the price of allergy treatment EpiPens by more than 400 percent over the past nine years, calling the decision part of a larger pattern among drug makers.

Clinton is the latest politician to express outrage over the price hike, which is the most recent in a line of huge increases by drug makers.

The Democratic nominee for president said on Facebook that it's wrong when "drug companies put profits ahead of patients, raising prices without justifying the value behind them."

"That's outrageous — and it's just the latest troubling example of a company taking advantage of its consumers."

Other examples of price increases that elicited similar anger include the steep cost of $1,000 a pill for hepatitis C cure Sovaldi and the decision by small biotech firm Turing Pharmaceuticals to raise the price of the generic anti-malarial drug Daraprim from $13 a pill to $750.

The increases have prompted a slew of publicity on high drug prices, with both Clinton and Trump criticizing the pharmaceutical industry.

Clinton on Facebook pointed to her plan to tackle high prices. It includes a provision that requires drug makers such as Mylan to explain the reason for big increases and prove that any additional costs "are linked to additional patient benefits and better value," the post reads.

Trump has said he supports allowing the federal government to negotiate for lower prices for Medicare drugs, which is prohibited under federal law.

On Capitol Hill, lawmakers are calling for a hearing on EpiPens, a popular allergy treatment.

Rep. Elijah Cummings, D-Md., said on Wednesday that Mylan's EpiPen hike didn't surprise him given other instances of high-profile drug prices. He has pushed for a hearing in the House Oversight Committee, which is looking into the issue.